Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising
Novo Nordisk, the maker of Ozempic and Wegovy, has filed a lawsuit against Eli Lilly, alleging that Eli Lilly's advertisements for its weight-loss drug Zepbound make deceptive claims comparing its effectiveness to Wegovy. The lawsuit, filed in Cleveland-Akron (Canton), claims…
Cleveland Akron, OH, July 21, 2026 — Novo Nordisk, the pharmaceutical company behind the popular weight-loss medications Ozempic and Wegovy, has initiated legal action against competitor Eli Lilly. The lawsuit, filed in the U.S. District Court for the Northern District of Ohio, Western Division (Cleveland-Akron (Canton)), accuses Eli Lilly of making deceptive claims in its advertising for Zepbound, a weight-loss drug manufactured by Eli Lilly.
At the core of Novo Nordisk’s complaint are allegations that Eli Lilly’s advertisements for Zepbound inaccurately compare the drug’s effectiveness to that of Novo Nordisk’s Wegovy. According to the lawsuit, these advertisements utilize outdated clinical trial data, which Novo Nordisk asserts misrepresents the comparative efficacy of the two medications. Novo Nordisk is seeking to have these allegedly deceptive advertisements withdrawn from circulation.
In addition to requesting the removal of the advertisements, Novo Nordisk is also seeking financial damages from Eli Lilly. The specific amount of damages sought was not detailed in the initial filing. The legal dispute highlights the competitive landscape in the rapidly growing market for weight-loss drugs.
Story summarized from the original created by Scripps News Group on www.news5cleveland.com, see more information here.
